Syndax Pharmaceuticals Inc (SNDX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 50M 100M 150M Q2 '15: 17K Q3 '15: 305K Q4 '15: 305K Q1 '16: 305K Q2 '16: 305K Q3 '16: 305K Q4 '16: 305K Q1 '17: 305K Q2 '17: 305K Q3 '17: 305K Q4 '17: 1.2M Q1 '18: 379K Q2 '18: 379K Q3 '18: 379K Q4 '18: 380K Q1 '19: 379K Q2 '19: 379K Q3 '19: 379K Q4 '19: 380K Q1 '20: 379K Q2 '20: 379K Q3 '20: 379K Q4 '20: 380K Q1 '21: 379K Q2 '21: 379K Q3 '21: 12.4M Q4 '21: 126.6M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 3.5M Q3 '24: 12.5M Q4 '24: 7.7M Q1 '25: 20M Q2 '25: 38M Q3 '25: 45.9M Q4 '25: 68.7M Q1 '26: 64.9M Q2 '26: 72.8M Q2 '16 Q4 '17 Q2 '19 Q4 '20 Q2 '23 Q4 '24 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q1 '15: -4.4M Q2 '15: -5.5M Q3 '15: -5.9M Q4 '15: -4.7M Q1 '16: -8.8M Q2 '16: -8.6M Q3 '16: -15.2M Q4 '16: -11.1M Q1 '17: -13.2M Q2 '17: -13.8M Q3 '17: -15.4M Q4 '17: -19.5M Q1 '18: -19.8M Q2 '18: -19M Q3 '18: -17.8M Q4 '18: -19.3M Q1 '19: -14.8M Q2 '19: -15.4M Q3 '19: -13.1M Q4 '19: -14.2M Q1 '20: -15.1M Q2 '20: -16.6M Q3 '20: -19.9M Q4 '20: -19.9M Q1 '21: -27.2M Q2 '21: -22.3M Q3 '21: -20M Q1 '22: -36.9M Q2 '22: -37.7M Q3 '22: -35.1M Q4 '22: -42M Q1 '23: -46M Q2 '23: -49.7M Q3 '23: -56.4M Q4 '23: -77.9M Q1 '24: -79.5M Q2 '24: -74.2M Q3 '24: -89.6M Q4 '24: -96.4M Q1 '25: -83.8M Q2 '25: -69.4M Q3 '25: -57.4M Q4 '25: -62.5M Q1 '26: -34.2M Q2 '26: -40M Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '21 Q2 '23 Q4 '24 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q1 '15: -4.9M Q2 '15: -6.2M Q3 '15: -7.7M Q4 '15: -5.3M Q1 '16: -10.3M Q2 '16: -8.4M Q3 '16: -15M Q4 '16: -10.8M Q1 '17: -13M Q2 '17: -13.6M Q3 '17: -15.1M Q4 '17: -19.1M Q1 '18: -19.4M Q2 '18: -18.4M Q3 '18: -17.3M Q4 '18: -18.8M Q1 '19: -14.3M Q2 '19: -14.9M Q3 '19: -12.8M Q4 '19: -14M Q1 '20: -15.2M Q2 '20: -17.1M Q3 '20: -20.4M Q4 '20: -20.4M Q1 '21: -27.7M Q2 '21: -22.9M Q3 '21: -20.6M Q1 '22: -37.2M Q2 '22: -37.6M Q3 '22: -35.4M Q4 '22: -39.2M Q1 '23: -41.1M Q2 '23: -44.6M Q3 '23: -51.1M Q4 '23: -72.5M Q1 '24: -72.4M Q2 '24: -68.1M Q3 '24: -84.1M Q4 '24: -94.2M Q1 '25: -84.8M Q2 '25: -71.8M Q3 '25: -60.7M Q4 '25: -68M Q1 '26: -42.7M Q2 '26: -49.4M Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-105M -70M -35M 0 35M 70M 105M Q1 '15: 11M Q2 '15: -4M Q3 '15: -5.2M Q4 '15: -4.3M Q1 '16: -6.4M Q2 '16: -6.9M Q3 '16: -11.4M Q4 '16: -10.4M Q1 '17: -12.7M Q2 '17: -11.8M Q3 '17: -10.2M Q4 '17: -12.7M Q1 '18: -19.9M Q2 '18: -15.1M Q3 '18: -18.5M Q4 '18: -15M Q1 '19: -16.8M Q2 '19: -12.5M Q3 '19: -8.5M Q4 '19: -12.7M Q1 '20: -15.9M Q2 '20: -21.4M Q3 '20: -18.3M Q4 '20: -15.6M Q1 '21: -22.6M Q2 '21: -24M Q3 '21: -24.9M Q1 '22: -41.9M Q2 '22: -40.3M Q3 '22: -28.5M Q4 '22: -22.9M Q1 '23: -39.2M Q2 '23: -35.4M Q3 '23: -44.7M Q4 '23: -41.3M Q1 '24: -83.5M Q2 '24: -71.6M Q3 '24: -62.3M Q4 '24: -57.4M Q1 '25: -95.2M Q2 '25: -87.8M Q3 '25: -70.5M Q4 '25: -69.5M Q1 '26: -50.3M Q2 '26: -30.3M Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '15: -5.2M Q4 '15: -4.3M Q1 '16: -6.5M Q2 '16: -7M Q3 '16: -11.5M Q4 '16: -10.4M Q4 '17: -12.8M Q1 '18: -20M Q2 '18: -15.1M Q3 '18: -18.5M Q4 '18: -15.1M Q3 '15 Q1 '16 Q3 '16 Q4 '17 Q2 '18 Q4 '18

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '21: 51.6M Q3 '21: 52M Q1 '22: 59M Q2 '22: 60.2M Q3 '22: 60.7M Q1 '23: 69.4M Q2 '23: 69.6M Q3 '23: 69.9M Q1 '24: 85.2M Q2 '24: 85.3M Q3 '24: 85.4M Q1 '25: 86.2M Q2 '25: 86.3M Q3 '25: 86.6M Q1 '26: 88.3M Q2 '26: 89M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1800.00 -1200.00 -600.00 0.00 600.00 1200.00 1800.00 Q4 '15: -1543.24 Q1 '16: -1339.79 Q2 '16: -899.74 Q3 '16: -109.73 Q4 '16: -4.75 Q1 '17: -2.61 Q2 '17: -2.84 Q3 '17: -2.68 Q4 '17: -2.89 Q1 '18: -2.97 Q2 '18: -3.01 Q3 '18: -3.01 Q4 '18: -1.51 Q1 '19: -1.25 Q2 '19: -0.98 Q3 '19: -0.71 Q4 '19: -1.85 Q1 '20: -1.88 Q2 '20: -1.83 Q3 '20: -1.88 Q4 '20: -1.88 Q1 '21: -1.86 Q2 '21: -1.88 Q3 '21: -1.82 Q4 '22: -2.45 Q1 '23: -2.41 Q2 '23: -2.43 Q3 '23: -2.58 Q4 '23: -2.97 Q1 '24: -3.23 Q2 '24: -3.39 Q3 '24: -3.64 Q4 '24: -3.72 Q1 '25: -3.85 Q2 '25: -3.88 Q3 '25: -3.60 Q4 '25: -3.29 Q1 '26: -2.79 Q2 '26: -2.51 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.